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NMDA receptors (NMDARs) are required for experience-driven plasticity during formative periods of brain development and are critical
for neurotransmission throughout postnatal life. Most NMDAR functions have been ascribed to postsynaptic sites of action, but there is
now an appreciation that presynaptic NMDARs (preNMDARs) can modulate neurotransmitter release in many brain regions, including
the neocortex. Despite these advances, the cellular mechanisms by which preNMDARs can affect neurotransmitter release are largely
unknown. Here we interrogated preNMDAR functions pharmacologically to determine how these receptors promote spontaneous neu-
rotransmitter release in mouse primary visual cortex. Our results provide three new insights into the mechanisms by which preNMDARs
can function. First, preNMDARs can enhance spontaneous neurotransmitter release tonically with minimal extracellular Ca 2 or with
major sources of intracellular Ca 2 blocked. Second, lowering extracellular Na  levels reduces the contribution of preNMDARs to
spontaneous transmitter release significantly. Third, preNMDAR enhance transmitter release in part through protein kinase C signaling.
These data demonstrate that preNMDARs can act through novel pathways to promote neurotransmitter release in the absence of action
potentials.
Introduction
NMDA receptors (NMDARs) are critical for a wide range of neu-
ral functions, including memory formation, injury responses,
and proper wiring of the developing nervous system (Cull-Candy
et al., 2001; Pérez-Otaño and Ehlers, 2004; Lau and Zukin, 2007).
Not surprisingly, NMDAR dysfunction has been implicated in a
number of neurological disorders, including schizophrenia, Alz-
heimer’s disease, epilepsy, ethanol toxicity, pain, depression, and
certain neurodevelopmental disorders (Rice and DeLorenzo,
1998; Cull-Candy et al., 2001; Sze et al., 2001; Mueller and
Meador-Woodruff, 2004; Coyle, 2006; Fan and Raymond, 2007;
Autry et al., 2011). As a consequence, NMDARs are targets for
many therapeutic drugs (Kemp and McKernan, 2002; Lipton,
2004; Autry et al., 2011; Filali et al., 2011).
Although most researchers have assumed a postsynaptic role
for NMDARs, there is now compelling evidence that NMDARs
can be localized presynaptically, where they are well positioned to
regulate neurotransmitter release (Hestrin et al., 1990; Aoki et al.,
1994; Charton et al., 1999; Corlew et al., 2007; Corlew et al., 2008;
Larsen et al., 2011). Indeed, NMDARs can regulate spontaneous
and evoked neurotransmitter release in the cortex and hip-
pocampus in a developmental and region-specific manner
(Berretta and Jones, 1996; Mameli et al., 2005; Corlew et al., 2007;
Brasier and Feldman, 2008; McGuinness et al., 2010; Larsen et al.,
2011). Presynaptic NMDARs (preNMDARs) are also critical for
the induction of spike timing-dependent long-term depression
(Sjöström et al., 2003; Bender et al., 2006; Corlew et al., 2007;
Larsen et al., 2011), a candidate plasticity mechanism for refining
cortical circuits and receptive field maps (Yao and Dan, 2005).
The precise anatomical localization of preNMDARs has been de-
bated (Christie and Jahr, 2008; Corlew et al., 2008; Christie and
Jahr, 2009), but recent studies have shown that axonal NMDARs,
rather than dendritic or somatic NMDARs on the presynaptic
neuron, can increase the probability of evoked neurotransmitter
release in the hippocampus (McGuinness et al., 2010; Rossi et al.,
2012) and are required for timing-dependent long-term depres-
sion in the neocortex (Sjöström et al., 2003; Rodríguez-Moreno
et al., 2010; Larsen et al., 2011). In addition to an increased un-
derstanding of the anatomical localization of preNMDARs, the
molecular composition of preNMDARs is beginning to be eluci-
dated. There is general agreement that cortical preNMDARs con-
tain the GluN2B subunit (Bender et al., 2006; Brasier and
Feldman, 2008; Larsen et al., 2011). At least in the developing
visual cortex, preNMDARs require the GluN3A subunit to pro-
mote spontaneous, action-potential-independent transmitter re-
lease (Larsen et al., 2011).
However, despite advances in understanding the roles and
molecular composition of preNMDARs, the cellular processes of
preNMDAR-mediated release are poorly understood. Here we
used a common assay for preNMDAR functions to probe phar-
macologically the mechanisms by which these receptors promote
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spontaneous neurotransmitter release. Surprisingly, we found
that preNMDARs can function in the virtual absence of extracel-
lular Ca 2 in a protein kinase C (PKC)-dependent manner. Fur-
thermore, in normal Ca 2 conditions, lowering extracellular
Na or inhibiting PKC activity reduces preNMDAR-mediated
enhancement of spontaneous transmitter release. These results pro-
vide new insights into the mechanisms by which preNMDARs
function.
Materials and Methods
Subjects. C57BL/6 mice were purchased from Charles River Laboratories
and then bred and maintained at the University of North Carolina. Ex-
periments were conducted between postnatal day 13 (P13) and P18 in
mice of either sex. Mice were kept in a 12 h light/dark cycle and were
provided food and water ad libitum. All experiments were conducted
under the animal care guidelines for the University of North Carolina at
Chapel Hill.
Cortical slice preparation. Mice were decapitated following anestheti-
zation with pentobarbital Na  (40 mg/kg, i.p.). Brains were removed
and placed in ice-cold dissection buffer bubbled with 95% O2 and 5%
CO2. Dissection buffered consisted of the following (in mM): 87 NaCl, 2.5
KCl, 1.25 NaH2PO4, 25 NaHCO3, 75 sucrose, 10 dextrose, 1.3 ascorbic
acid, 7 MgCl2, and 0.5 CaCl2. Next, 300 M coronal slices of the visual
cortex were cut using a vibrating microtome (VT1200S; Leica). Slices
were placed for 20 min in a submersion chamber at 35°C containing
artificial CSF (ACSF) containing the following (in mM): 124 NaCl, 3 KCl,
1.25 Na2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2, and 20 D-glucose saturated
with 95% O2 and 5% CO2 at 315 mOsm and pH 7.25. After the initial 20
min recovery period, slices were allowed to recover for an additional 40
min at room temperature, where they were maintained until use. For
electrophysiological recordings, visual cortex slices were placed in a sub-
mersion chamber warmed to 30°C and perfused with oxygenated ACSF.
Borosilicate glass pipettes had an open tip resistance between 3 and 6 M
when filled with an internal solution containing the following (in mM):
20 KCl, 100 (K)gluconate, 10 HEPES, 4 (Mg)ATP, 0.3 (Na)GTP, 10 (Na)
phosphocreatine, and 1 MK-801 with pH adjusted to 7.25 and osmolarity
adjusted to 300 mOsm with sucrose. All recordings were performed in
whole-cell configurations using a patch-clamp amplifier (Multiclamp
700A/B; Molecular Devices) and were acquired and analyzed using
pClamp 9.2 or 10.2 software (Molecular Devices).
Current-clamp recordings. Action potentials were evoked either by ex-
ternal stimulation or by direct current injection into the postsynaptic
cell. For extracellular-evoked experiments, layer (L) 2/3 pyramidal cells
were recorded while L4 axons were stimulated every 30 s with a two-
conductor cluster electrode (FHC). Current was injected to maintain a
70 mV resting potential if necessary. Action potentials were evoked for
5 min before a 10 min TTX (200 nM) application. To examine the effect of
TTX on postsynaptic spike firing, current (300 pA, 400 ms) was injected
before and after a 10 min TTX application.
Voltage-clamp recordings. Miniature EPSCs (mEPSCs) were recorded
in the presence of the GABAA receptor antagonist picrotoxin (50 M) and
the voltage-gated Na  channel blocker TTX (200 nM). Neurons were
recorded while holding the postsynaptic neuron at 80 mV; only cells
with Rseries  30 M and having 20% change in Rinput, Rseries, and
Iholding were included in analysis. The combination of strong hyperpo-
larization and inclusion of MK-801 in the postsynaptic pipette nearly
abolishes postsynaptic NMDAR activity (Corlew et al., 2007). To mea-
sure the effects of preNMDARs on synaptic function, we measured
mEPSC amplitude and frequency before and after bath application of 50
M D-APV (Fig. 1A). All statistical comparisons were made between
segments of the baseline period (last 5–10 min) and the APV application
period (last 5–10 min of application). Greater than 50 mEPSCs were
analyzed for each comparison period in a single experiment (Turrigiano
et al., 1998). Interleaved control experiments were performed for the
same duration but without APV application to verify that the pharma-
cological agents did not affect the stability of the electrophysiological
recordings (data not shown for most experiments). mEPSCs were de-
tected using an automatic template detection program and verified man-
ually (pCLAMP; Molecular Devices; Clements and Bekkers, 1997).
Pharmacological agents. D-APV, TTX, and okadaic acid were purchased
from Ascent Scientific. Picrotoxin, thapsigargin, dantrolene, and canthara-
din were purchased from Sigma-Aldrich. 1-(5-Isoquinolinesulfonyl)-2-
methylpiperazine (H7), KT5720, and GF 109203X (GFX) were purchased
from Tocris Bioscience. Cyclopiazonic acid (CPA) and EGTA were pur-
chased from EMD and Fisher Scientific, respectively.
Statistics. Data are reported as mean  SEM unless noted otherwise,
and statistical significance was assessed using two-tailed paired or un-
paired Student’s t tests with significance placed at p  0.05. For compar-
ison of multiple groups, a one-way ANOVA was used; a Tukey–Kramer
multiple-comparisons test was used for the post hoc analyses; statistical
significance was defined as p  0.05.
Results
PreNMDARs can enhance neurotransmitter release with
minimal Ca 2 requirements
Recent studies demonstrated that NMDA application can evoke
axonal Ca 2 responses (Lin et al., 2010; McGuinness et al.,
2010; Buchanan et al., 2012), consistent with findings that
preNMDARs can promote neurotransmitter release via Ca 2-
dependent mechanisms (Berretta and Jones, 1996; Cochilla and
Alford, 1999; Woodhall et al., 2001; Mameli et al., 2005). There-
fore, we decided to determine the signaling cascades downstream
of preNMDAR activation by first clarifying the requirements for
Ca 2. To determine the mechanisms of preNMDAR-mediated
transmitter release, we examined the effects of NMDAR blockade
on spontaneous release in the presence of TTX (200 nM). In 9 of 9
experiments, a 5 min application of this TTX concentration ef-
fectively blocked spike formation in L2/3 neurons in response to
direct current injection or L4 extracellular stimulation (Fig. 1A).
In addition to performing experiments in the presence of TTX, in
subsequent experiments, we first blocked postsynaptic NMDARs
by including the NMDAR antagonist MK-801 in the recording
pipette and by strongly hyperpolarizing the postsynaptic neu-
ron (Corlew et al., 2007). We then determined the role of
preNMDARs in spontaneous transmitter release by examining
how bath application of the competitive NMDAR antagonist
D-APV (50 M) altered postsynaptic AMPAR-mediated
mEPSCs. As demonstrated previously under these control con-
ditions (Corlew et al., 2007; Brasier and Feldman, 2008; Corlew et
al., 2008; Larsen et al., 2011), bath application of APV reduced
mEPSC frequency but not amplitude (Fig. 1B), indicating that
preNMDARs tonically facilitate glutamate release. To determine
the extent to which preNMDARs require Ca 2 to promote neu-
rotransmitter release, we examined the effects of APV on spon-
taneous transmitter release in neurons recorded in ACSF lacking
external Ca 2 and with EGTA (3 mM) to further buffer residual
Ca 2. These low Ca 2 conditions profoundly reduced mEPSC
frequency compared with controls with normal ACSF (p  0.05;
note different axes and average baseline values in Fig. 1B3 and Fig.
1C2). However, even in the nominally zero Ca
2 ACSF, APV
application reduced mEPSC frequency (p  0.05), but not am-
plitude, compared with baseline (Fig. 1C). mEPSC frequency re-
turned to baseline levels after APV was removed, indicating that
this decrease was specific to APV application and was not a gen-
eral rundown of cellular responses (Fig. 1C2). Moreover, the nor-
malized reduction in mEPSC frequency by APV in nominally
zero Ca 2 ACSF was not statistically different (p  0.82) than the
normalized reduction in mEPSC frequency by APV in normal
Ca 2 ACSF (Fig. 1C3). These data suggest that preNMDARs are
able to promote spontaneous neurotransmitter release with min-
imal Ca 2 entry from extracellular sources.
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PreNMDAR-mediated enhancement of spontaneous
transmitter release does not require Ca 2 release from
intracellular stores
Recent work has suggested that preNMDARs function through
Ca 2-induced Ca 2 release (Rossi et al., 2012). Therefore, we
next investigated whether intracellular Ca 2 stores were required
for preNMDAR-mediated release of glutamate (Fig. 2) using
pharmacological agents that disrupt release of Ca 2 from intra-
cellular stores and that have been shown previously to affect
spontaneous release (Simkus and Stricker, 2002; Collin et al.,
2005). For all experiments, we first determined whether the phar-
macological agent being used affected spontaneous release. Some
drugs affected the baseline frequency of mEPSCs, however, we
were still able to determine whether APV could modulate the
drug-modified baseline. To determine the consequences of the
SERCA sarco/endoplasmic reticulum Ca 2-ATPase pump an-
tagonist, cyclopiazonic acid, (CPA; 30 M), we first bathed visual
cortex slices in CPA for at least 1 h (thereby depleting and inhib-
iting release of Ca 2 from these intracellular stores) (Simkus and
Stricker, 2002). Despite blocking release from SERCA-sensitive
intracellular stores, we still found that APV application signifi-
cantly reduced mEPSC frequency (p  0.05) without modifying
amplitude (p  0.12; Fig. 2B). Further, the normalized reduction
in mEPSC frequency was not significantly different from slices
incubated in normal ACSF (p  0.45). To confirm these results,
we next investigated the influence of another SERCA inhibitor,
thapsigargin (4 M), compared with control conditions (Fig. 2C).
As with CPA, visual cortex slices were exposed to thapsigargin for
Figure 1. PreNMDARs can tonically promote neurotransmitter release with minimal Ca 2 requirements. A1, Example trace of the response of a layer (L) 2/3 pyramidal neuron to a 300 pA current
pulse. After TTX (200 nM) was washed onto the slice for 5 min, no action potentials were observed. A2, Example trace measuring the response in a L2/3 pyramidal neuron to extracellular stimulation
of L4. Within 5 min of TTX application, a stimulation that previously could elicit a postsynaptic spike, failed to elicit a detectable EPSP. B1, Schematic of the experimental protocol used to delineate
the signaling pathways downstream of preNMDAR activation (see Materials and Methods and Results sections for details). B2, Example whole-cell recording depicting mEPSCs (arrows) from a L2/3
pyramidal cell in a visual cortex slice from a P15 mouse. B3, Scatterplot of mEPSC frequency from individual recordings in normal ACSF (baseline) demonstrating that D-APV (50 M) antagonism of
preNMDARs reversibly reduces mEPSC frequency in L2/3 pyramidal neurons. Group means (depicted by red bar) and SDs are as follows: baseline, 2.31  1.2; APV, 1.59  0.86; and wash, 2.14 
1.19. B4, Bar chart depicting the effects of APV application on the normalized mEPSC frequency and amplitude. C1, Example whole-cell recording from an L2/3 pyramidal cell recorded in ACSF with
nominally zero Ca 2. C2, APV reversibly decreases mEPSC frequency in neurons recorded in nominally zero Ca
2 [paired t test; t (8)  6.73, p  0.001]. Group means (depicted by red bar) and SD
are as follows: baseline, 0.63  0.43; APV, 0.47  0.42; and wash, 0.59  0.55. C3, Bar graph displaying the normalized and averaged effect of APV treatment on the normalized mEPSC frequency
and amplitude in experiments performed in control conditions with normal Ca 2 versus zero Ca 2 conditions. No statistical differences in APV effects were observed (unpaired t tests; frequency:
t(12)  0.62, p  0.82; amplitude: t(12)  1.57, p  0.14). In control experiments, no changes in mEPSC frequency or amplitude were observed in neurons recorded in zero Ca
2 over the same time
course but in the absence of APV treatment (paired t tests; frequency: t(4)  0.37, p  0.73; amplitude: t(4)  1.66, p  0.17)]. Asterisk denotes significant differences from baseline. Error bars
represent SEM.
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at least 1 h before recording. In the presence of thapsigargin, APV
application reduced mEPSC frequency (p  0.05) without affect-
ing amplitude (p  0.27). Further, the effects of APV on mEPSC
frequency under control and thapsigargin-treated slices were statis-
tically indistinguishable (p  0.15). These data suggest that preN-
MDARs do not require activation of SERCA-mediated Ca2 stores
to promote spontaneous transmitter release.
Finally, to test for a requirement of Ca 2 release from
ryanodine-sensitive stores, we incubated visual cortex slices in
the ryanodine antagonist dantrolene (10 M) for at least 1 h
before recordings (Fig. 2D). Under these conditions, APV appli-
cation still reduced mEPSC frequency (p  0.05) without affect-
ing mEPSC amplitude (p  0.78). Further, dantrolene-treated
and control slices responded similarly to APV treatment (p 
0.43). These data indicate that preNMDARs can promote spon-
taneous transmitter release in a manner that can be independent
of Ca 2 release from intracellular stores.
PreNMDARs require Na -dependent depolarization to
enhance tonic transmitter release
We were surprised that preNMDARs could continue to promote
presynaptic neurotransmitter release in nominally zero Ca 2
conditions. We therefore sought to determine additional mech-
anisms that could contribute to preNMDAR-mediated transmit-
ter release. Because preNMDARs can spontaneously promote
neurotransmitter release in the absence of action potentials and
spontaneous preNMDAR activity in the visual cortex requires
GluN3A-containing NMDARs (Larsen et al., 2011), which are
known to have reduced Ca 2 permeability (Das et al., 1998;
Pérez-Otaño et al., 2001; Matsuda et al., 2002; Sasaki et al., 2002;
Tong et al., 2008), we hypothesized that Na-dependent depo-
larization may serve as an important contributor to preNMDAR-
mediated release. Depolarization can influence presynaptic
release directly by influencing voltage-gated Ca 2 channels or
indirectly through the activation of intracellular signaling cas-
cades (Leenders and Sheng, 2005). To determine the influence of
depolarization, we replaced either 50% (final concentration of 62
mM) or 75% (final concentration of 31 mM) of the extracellular
NaCl with the impermeable monovalent cation N-methyl-D-
glucamine (Fig. 3). We could not completely remove Na from
the extracellular solution because Na flow through AMPA re-
ceptors is required to measure our primary readout, AMPAR-
mediated currents. As expected, lowering NaCl to 31 mM
significantly reduced mEPSC frequency and amplitude in base-
line conditions (p  0.05) through a large reduction in the driv-
ing force. This large reduction (31 mM) in extracellular sodium
was sufficient to block the reduction in mEPSC frequency by APV
(p  0.93, paired t test; Fig. 3B). However, reducing extracellular
NaCl to 62 mM was not sufficient to block the APV-mediated
reduction in mEPSC frequency (p  0.05; paired t test). In addi-
tion, an ANOVA comparing the APV-induced change in normal-
ized mEPSC frequency in the low 31 mM Na group, the 62 mM
Na group, and the 124 mM Na group (controls) yielded a
significant main effect (p  0.05). Post hoc tests to probe this
significant difference indicated that the 31 mM Na group
Figure 2. Calcium release from intracellular stores is not required to promote tonic
preNMDAR-mediated enhancement of neurotransmitter release. A, Schematic of the experi-
mental protocol. B–D, Scatterplots (left) indicate a significant reduction in mEPSC frequency for
experiments performed in the presence of the SERCA inhibitors (CPA and thapsigargin) or a
ryanodine antagonist (dantrolene). Group means (depicted by red bar) and SDs are as follows:
CPA baseline, 5.88  0.84; CPA APV, 4.8  0.42; thapsigargin baseline, 7.15  3.91; thapsi-
gargin APV, 5.8  3.82; dantrolene baseline, 6.52  2.32; and dantrolene APV, 5.29  2.20.
Paired t tests for all groups demonstrated that APV effectively reduced mEPSC frequency (CPA:
t(5)  2.75, p  0.05; thapsigargin: t(9)  5.01, p  0.001; dantrolene: t(7)  4.84, p  0.01).
Bar graphs (right) display the normalized and averaged changes in mEPSC frequency and am-
plitude by APV treatment in neurons recorded in the presence of CPA, thapsigargin, dantrolene,
or their interleaved controls (Cont). CPA, thapsigargin, and dantrolene treatments did not
significantly affect the APV-induced reduction in mEPSC frequency compared with control
4
experiments performed in normal ACSF (CPA: t(10) 0.78, p0.45; thapsigargin: t(16) 1.41,
p  0.15; dantrolene: t(12)  0.88, p  0.43), nor did these treatments affect the lack of APV
influence on mEPSC amplitude (CPA: t(10)  0.20, p  0.85; thapsigargin: t(16)  0.50, p 
0.20; dantrolene: t(12)  0.93, p  0.62). Asterisk denotes significant differences from base-
line. Error bars represent SEM.
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showed less APV-induced modification
of normalized mEPSC frequency com-
pared with either the 62 mM Na  group
or the 124 mM Na  group (control).
Normalized mEPSC amplitude was not
modified by APV application, because
ANOVA failed to detect a significant
difference between the various Na 
treatments ( p  0.60).
Presynaptic HCN channels have been
shown to significantly affect presynaptic
release at excitatory synapses (Huang et
al., 2011). Reduction of the Na driving
force could also block modulation of neu-
rotransmitter release by HCN channels
and potentially confound the interpreta-
tion of our APV results. To exclude the
possibility that HCN channels contribute
to preNMDAR function, we sought to
determine whether APV could modify
presynaptic release in the presence of the
HCN channel inhibitor Zd 7288. In the
presence (Fig. 3F) or absence (Fig. 3G) of
extracellular Ca 2, Zd 7288 failed to block
the reduction in mEPSC frequency com-
pared with control solutions (p  0.05),
suggesting that HCN channels do not
contribute to mEPSC frequency in a
preNMDAR-dependent manner. These
data suggest that Na-dependent pro-
cesses are important for preNMDAR-
mediated transmitter release, but only
modest extracellular Na levels are
needed. However, these data do not deter-
mine whether Na flow depolarizes the
presynaptic terminal directly, thus affect-
ing transmitter release, or if Na-induced
depolarization begins a signaling cascade
that is critical toward enhancing presyn-
aptic function.
Influence of kinase and phosphatase
pathways on preNMDAR-mediated
transmitter release
Having established a role for Na influx
in preNMDAR function, which likely
works in addition to the established role
for Ca 2-mediated effects (Lin et al.,
2010; McGuinness et al., 2010), we then
began to investigate downstream signal-
ing cascades. Because the phosphoryla-
Figure 3. Partial replacement of Na  with N-methyl-D-glucamine blocks the tonic activity of preNMDARs. A1, Schematic
depicting the experimental protocol used to test the contributions of Na  for preNMDAR function. A2, Representative voltage-
clamp recordings from an experiment performed in low Na  (31 mM). B, Scatterplots indicating mEPSC frequency for experiments
performed in 31 and 62 mM Na  during the baseline period and during APV application. APV application failed to consistently
reduce mEPSC frequency in neurons recorded in in 31 mM extracellular Na  (t(11)  0.81, p  0.2), but did reduce mEPSC
frequency in 62 mM Na  (t(13)  2.03, p  0.01). Group means (depicted by red bar) and SDs are as follows: 31 mM baseline,
0.64  0.24; 31 mM APV, 0.64  0.26; 62 mM baseline, 3.92  1.67; 62 mM APV, 3.30  1.45; 124 mM baseline, 4.01  1.50; and
124 mM APV, 3.04  1.38. C, Bar graph displaying the normalized and averaged mEPSC frequency and amplitude in neurons
recorded in 31 mM extracellular NaCl, 62 mM extracellular NaCl, and in control 124 mM extracellular NaCl. The 62 mM and the 124 mM
NaCl groups were significantly more sensitive to APV wash compared with the 31 mM group as indicated by an ANOVA (F(2,35) 
6.78, p  0.004) and subsequent post hoc tests ( p  0.05). No significant differences in mESPC amplitude were observed (ANOVA;
F(2,35)  0.51, p  0.60). Asterisks denote significant differences. D, Average cumulative probability distributions of mEPSC
frequency and amplitude under baseline conditions or during APV application. APV application shortened interevent intervals in
the presence of 62 and 124 mM NaCl, but not 31 mM NaCl, and had no effect on amplitude, regardless of NaCl concentration. For
cumulative probability plots, the same number of events were analyzed for each neuron within a condition so that interneuron
differences in frequency would not skew the analysis. E, Representative voltage-clamp recordings from an experiment performed
in Zd 7288. F–G, Scatterplot (left) indicates a significant reduction in mEPSC frequency for experiments performed with or without
external Ca 2 in the presence of the Zd 7288, an HCN inhibitor. Paired t tests demonstrate that APV reduced mEPSC frequency in
either condition (normal ACSF: t(6)  4.50, p  0.01; zero Ca
2 ACSF: t(9)  3.33, p  0.01). Group means (depicted by red bar)
and SDs are as follows: Zd 7288 baseline, 3.20  1.40; Zd 7288 APV, 2.35  1.27; zero Ca 2 Zd 7288 baseline, 1.03  0.35; and
zero Ca 2 Zd 7288 APV, 0.72  0.24. Bar graphs (right) display the normalized and averaged changes in mEPSC frequency and
4
amplitude by APV treatment in neurons recorded in the pres-
ence of Zd 7288 or the interleaved controls. Zd 7288 did not
significantly affect the APV-induced reduction in mEPSC
frequency compared with control experiments performed in
normal ACSF (t(11)  0.56, p  0.23) or zero Ca
2 ACSF
(t(13)  1.37, p  0.19), nor did these treatments affect the
lack of APV influence on mEPSC amplitude (normal ACSF:
t(11)  1.35, p  0.21; zero Ca
2 ACSF: t(13)  0.15, p 
0.88). Asterisk denote significant differences from baseline.
Error bars represent SEM.
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tion state of presynaptic proteins has a profound influence upon
presynaptic efficacy (Leenders and Sheng, 2005), we investigated
whether phosphatase or kinase activation was required for
preNMDAR-dependent transmitter release.
We found no evidence that blocking phosphatase activity with
cantharidin (10 M) or okadaic acid (1 M) could affect
preNMDAR-mediated enhancement of transmitter release (data
not shown), so we sought to determine the role of kinase activity
on this phenomenon using a broad-spectrum kinase inhibitor,
H7. After incubating our slices in H7 (10 M) for at least 1 h (Fig.
4B), we observed a significant reduction in mEPSC frequency
from baseline in response to APV (p  0.05), with no change in
mEPSC amplitude (p  0.35). However, when the normalized
reduction in mEPSC frequency by APV was compared between
the control group and the H7 group, we observed a significant
difference (p  0.05). These findings sug-
gest that kinase activity is at least partially
required for preNMDARs to influence
presynaptic release. Because H7 is a broad
kinase inhibitor, we next sought to deter-
mine which specific kinases influenced
preNMDAR activity by incubating the
slices in KT5720 (1 M), a PKA inhibitor.
APV significantly reduced mEPSC fre-
quency in the presence of KT5720 (data
not shown; p  0.05). No changes in
mEPSC amplitude were observed (p 
0.54). When we compared the normalized
reduction in mEPSC frequency with a
control group given APV in normal
ACSF, no significant difference was ob-
served (p  0.95), suggesting that PKA
activity was not required for preNMDARs
to affect presynaptic transmitter release.
We next investigated the role of PKC by
bathing our slices in GFX (10 M), a spe-
cific inhibitor of PKC. APV failed to re-
duce mEPSC frequency in the presence of
GFX (p  0.05; Fig. 4C), with no change
in mEPSC amplitude (p  0.68). In addi-
tion, slices incubated with GFX were sig-
nificantly less sensitive to changes in
normalized mEPSC frequency during the
APV wash compared with the ACSF con-
trols (p  0.05). No change in mEPSC
amplitude was measured (p  0.53).
These data suggest that PKC activity is
partially required for preNMDAR func-
tion. We next sought to determine
whether these mechanisms contribute to
preNMDAR function in the modified
zero Ca 2 ACSF. In nominally zero Ca 2,
H7 and GFX still blocked the effect of APV
on mEPSC frequency without affecting
mEPSC amplitude [(H7: normalized
mEPSC frequency, p  0.05; normalized
mEPSC amplitude, p  0.69) and (GFX:
normalized mEPSC frequency, p  0.05;
normalized mESPC amplitude, p  0.73)]
compared with zero Ca2 ACSF controls
(Fig. 4D,E). This suggests that key mecha-
nisms for preNMDAR-mediated enhance-
ment of neurotransmitter release function
in the presence or absence of Ca2.
Discussion
The goal of this study was to help to elucidate the cellular mech-
anisms that operate downstream of preNMDAR activation to
enhance neurotransmitter release. Our evidence indicates that
the preNMDAR-dependent signaling pathways responsible for
enhancing presynaptic neurotransmitter release can operate in
nominally zero extracellular Ca 2. Further, we also show that
release of Ca 2 from intracellular stores is not required. Our
data demonstrate that preNMDARs can function with mini-
mal Ca 2 requirements and may even be able to function in a
Ca 2-independent manner. There is also good evidence that
preNMDARs may normally promote transmitter release through
Ca2-dependent mechanisms (Berretta and Jones, 1996; Cochilla
Figure 4. Role of kinase activity in tonic preNMDAR activity. A1, Schematic showing the experimental protocol used to test the
requirement of kinase activity for preNMDAR function. All inhibitors were bath applied for at least 1 h before experimentation.
A2–3, Representative voltage-clamp recordings from an experiment performed in the presence of the PKC inhibitor GFX in normal
or zero Ca 2 ACSF. B, C, Scatterplots (left) indicate significant reductions after APV application for experiments performed in the
broad kinase inhibitor H7 (paired t test: t(12)  2.91, p  0.01) and the PKC inhibitor GFX (paired t test: t(8)  1.72, p  0.05).
Group means (depicted by red bar) and SDs are as follows: H7 baseline, 2.45  0.67; H7 APV, 2.15  0.62; GFX baseline, 2.53 
1.21; and GFX APV, 2.10  0.74. Bar graphs (right) display the normalized mEPSC frequency for groups incubated and tested in H7
and GFX that were significantly different from the normalized frequency of groups incubated and tested in normal ACSF (unpaired
t tests: H7: t(17)  2.62, p  0.02; GFX: t(13)  0.45, p  0.03). No statistical differences in normalized mEPSC amplitude were
observed between groups tested in kinase inhibitors and normal ACSF (unpaired t tests; H7: t(17)  0.87, p  0.47; 10 M GFX:
t(13)  1.07, p  0.25). Asterisks denote significant differences. D, E, Scatterplots (left) indicate significant reductions after APV
application for experiments performed in zero Ca 2 ACSF in the presence of H7 (paired t test: t(7)  5.63, p  0.001) and GFX
(paired t test: t(9)  2.74, p  0.05). Group means (depicted by red bar) and SDs are as follows: zero Ca
2 H7 baseline, 0.55 
0.25; zero Ca 2 H7 APV, 0.48  0.21; zero Ca 2 GFX baseline, 0.89  0.43; and zero Ca 2 GFX APV, 0.83  0.43. Bar graphs
(right) display the normalized mEPSC frequency for groups incubated and tested in H7/zero Ca 2 ACSF and GFX/zero Ca 2 ACSF
that were significantly different from the normalized frequency of groups incubated and tested in zero Ca 2 ACSF (unpaired t
tests: H7: t(13)  4.63, p  0.001; GFX: t(14)  3.87, p  0.01). No statistical differences in normalized mEPSC amplitude were
observed between groups tested in kinase inhibitors and zero Ca 2 ACSF (unpaired t tests; H7: t(13)  0.55, p  0.59; GFX: t(14) 
0.35, p  0.73). Asterisks denote significant differences. Error bars represent SEM.
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and Alford, 1999; Woodhall et al., 2001; Mameli et al., 2005;
McGuinness et al., 2010; Buchanan et al., 2012). These data sug-
gest that there may be two mechanisms underlying preNMDAR-
influenced vesicular release: one that requires normal levels of
extracellular Ca 2 and another that can affect release in a largely
Ca 2-independent manner. Although we were surprised to see
that preNMDARs could continue to promote spontaneous trans-
mitter release with minimal Ca 2 requirements, this observation
is consistent with a recent finding from our laboratory indicating
that preNMDARs in the visual cortex are triheteromeric
NMDARs with low Ca 2 permeability (Larsen et al., 2011). Spe-
cifically, tonic preNMDAR activity appears to require GluN1,
GluN2B, and GluN3A subunits (Brasier and Feldman, 2008;
Larsen et al., 2011). These GluN3A-containing NMDARs have
interesting properties that make them ideally suited for a role in
presynaptic release. First, these NMDARs are relatively insensi-
tive to magnesium block near resting membrane potentials, al-
lowing them to function tonically in a non-Hebbian manner.
Second, these receptors have relatively low Ca 2 permeability,
consistent with our finding that extracellular Ca 2 may not be
required for tonic preNMDAR enhancement of transmitter re-
lease. We predict that NMDAR blockade by APV would not affect
mEPSC frequency in low Ca 2 solutions in visual cortical slices
from GluN3A knock-out mice, because the APV effect on
mEPSC frequency is lost in normal ACSF in these mice (Larsen et
al., 2011).
Although both Ca 2-dependent and Ca 2-independent
mechanisms support preNMDAR enhancement of transmitter
release, there is also an important contribution of Na influx to
preNMDAR-mediated transmitter release. The most parsimoni-
ous explanation is that Na influx provides depolarization of the
presynaptic terminal, which in turn activates a voltage-sensitive
signaling cascade that affects presynaptic release. However, we
cannot exclude the possibility that Na is serving as the second
messenger to mediate these effects. Nor can we rule out a role of
Na/Ca 2 exchange and subsequent effects upon voltage-gated
Ca 2 channels (Korn and Horn, 1989), or that Na could serve
directly to facilitate Ca 2 entry through preNMDARs. Further,
we cannot rule out other, less parsimonious interpretations of the
reduced Na experiments. Finally, presynaptic HCN channels
have been shown to modulate presynaptic release at glutamater-
gic synapses (Huang et al., 2011). Although these channels are
active at rest and would be affected by a low Na solution, we
found no evidence for their involvement in preNMDAR-
mediated spontaneous release.
The signaling cascades involved in preNMDAR enhancement
of transmitter release are largely unknown. Our data begin to
provide some insights because we demonstrate that blockade of
phosphatase activity fails to prevent preNMDAR enhancement of
spontaneous release. However, we did determine that kinase ac-
tivity, specifically PKC activity, helps to promote preNMDAR
transmitter release. It is difficult to determine whether PKC in-
volvement is direct or indirect—is PKC activated directly by
preNMDAR-mediated depolarization or by downstream signal-
ing cascades? PKC activity can facilitate transmitter release in
both a Ca 2-dependent and a Ca 2-independent manners
(Koponen et al., 1999; Saitoh et al., 2001; Scholze et al., 2002),
which is consistent with our observations that the Ca 2 require-
ments necessary to support preNMDAR-transmitter release can
be minimal.
Despite progress in determining the subunit composition, lo-
calization, and function of preNMDARs (Brasier and Feldman,
2008; Christie and Jahr, 2008; Corlew et al., 2008; Larsen et al.,
2011), there is still much to learn about how preNMDAR activity
promotes tonic transmitter release. We have begun to elucidate
this process by showing that tonic activation of preNMDARs en-
hances transmitter release through a depolarization-dependent
mechanism. Although preNMDARs enhance transmitter release
through Ca 2-dependent mechanisms (Berretta and Jones, 1996;
Cochilla and Alford, 1999; Woodhall et al., 2001; Mameli et al.,
2005; McGuinness et al., 2010; Buchanan et al., 2012), our work
shows that preNMDARs can continue to enhance transmit-
ter release with a minimal requirement for Ca 2 and that
preNMDARs enhance transmitter release in part through a PKC-
dependent pathway. These insights suggest that preNMDARs are
capable of promoting transmitter release via a noncanonical sig-
naling pathway that is largely independent of a direct link to
Ca 2-dependent release machinery, as well as through a more
traditional Ca 2-dependent pathway.
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